



2012 ESC STEMI guidelines and reperfusion therapy: Evidence base ignored, threatening optimal patient management

Citation

Terkelsen, C. J., D. S. Pinto, H. Thiele, P. Clemmensen, K. Nikus, J. F. Lassen, D. Hildick-Smith, et al. 2013. "2012 ESC STEMI guidelines and reperfusion therapy: Evidence base ignored, threatening optimal patient management." *Heart* 99 (16): 1154-1156. doi:10.1136/heartjnl-2013-304117. <http://dx.doi.org/10.1136/heartjnl-2013-304117>.

Published Version

doi:10.1136/heartjnl-2013-304117

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717609>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)



OPEN ACCESS

2012 ESC STEMI guidelines and reperfusion therapy

Evidence base ignored, threatening optimal patient management

Christian Juhl Terkelsen,¹ Duane S Pinto,² Holger Thiele,³ Peter Clemmensen,⁴ Kjell Nikus,⁵ Jens Flensted Lassen,¹ David Hildick-Smith,⁶ Evald Høj Christiansen,¹ Jens Aarøe,⁷ Hans-Henrik Tilsted Hansen,⁷ Goran Stankovic,⁸ Anders Junker,⁹ Georgios Sianos,¹⁰ Göran Olivecrona,¹¹ Hans Erik Bøtker,¹ Charles Michael Gibson,² Eric Boersma¹²

For numbered affiliations see end of article.

Correspondence to

Dr Christian Juhl Terkelsen, Department of Cardiology, B, Aarhus University Hospital in Skejby, Aarhus 8450, Denmark; chrterk@rm.dk

Published Online First
18 June 2013



Open Access
Scan to access more
free content



► <http://dx.doi.org/10.1136/heartjnl-2013-304498>

To cite: Terkelsen CJ, Pinto DS, Thiele H, *et al.* *Heart* 2013;**99**:1154–1156.

The 2012 European Society of Cardiology (ESC) ST-Elevation Myocardial Infarction (STEMI) guideline acknowledges that STEMI patients should receive reperfusion therapy as soon as possible, and that prehospital fibrinolysis or field-triage directly to Primary Percutaneous Coronary Intervention (PPCI) centres is the preferred reperfusion strategy.¹ However, when recommending fibrinolytic therapy (FT) within 30 min from First Medical Contact (FMC), if PPCI cannot be performed ‘within 60 min of FMC in patients presenting early, with a large amount of myocardium at risk’, the guidelines imply that only 30 min extra may be expended to perform PPCI instead of administering FT (‘PCI-related delay’) (figure 1).


Throughout the years, successive guidelines have mistakenly equated ‘PCI-related delay’ and ‘FMC to PPCI’ (the total delay from FMC to PPCI) (figure 1). This error persists in the recently updated ESC guideline.¹ Clarification of this distinction is of paramount importance because of the suggested reduction in the ‘window of opportunity for PPCI’, a suggestion not clearly supported by evidence, which has significant public health implications. In paragraph 3.5.2, the ESC STEMI guideline references a registry analysis from the National Registry of Myocardial Infarction (NRMI),² concluding: ‘primary PCI (wire passage) should be performed within 90 min after FMC in all cases. In patients presenting early, with a large amount of myocardium at risk, the delay should be shorter (<60 min).’ The NRMI reference is also listed in paragraph 3.4.1 in the ESC STEMI guideline when recommending the acceptable ‘FMC-to-PCI’ delay of only 60 min in early incomers with anterior infarction. However, this study describes ‘PCI-related delay’, that is, the theoretical extra delay that may be spent to perform PPCI over FT (figure 1). The NRMI manuscript by Pinto *et al.* does not describe ‘FMC-to-PCI’ delay in the cohorts evaluated since timing of Emergency Medical Service (EMS) evaluation was imprecise. The *only* delay data available

were the interval ‘Door-to-balloon (D2B)’ delay, which was 116 min when calculated as a weighted mean (table 1). Given the fact that ‘FMC-to-PCI’ is considerably longer than D2B delay among patients transported by EMS (figure 1), the ‘FMC-to-PCI’ delay is likely to have been considerably longer than 120 min (table 1). Consequently, these data cannot be applied recommendations regarding the optimal time to ‘FMC to PCI’ or to support a recommendation ‘of a systems goal of FMC to PCI of 60 min.’ It would appear that the 2012 STEMI guideline authors,¹ when compiling the overwhelming amount of scientific data, have either intended to use a different reference or misinterpreted the findings from Pinto *et al.*’s original work.² We are not aware of supportive data that would justify the current STEMI guideline recommendations to consider fibrinolysis within 30 min of FMC when PPCI cannot be performed within 60 min of FMC.

There have been several other studies addressing the optimal ‘PCI-related delay’. The initial study by Pinto and colleagues was limited by the fact that optimal FT (fibrin-specific drugs) was compared with a less-than-optimal PPCI strategy (PPCI centres performing only a mean of 20 PPCI procedures a year).² A later analysis by Pinto and colleagues found an acceptable ‘PCI-related delay’ of approximately 120 min without any excessive mortality in PPCI-treated patients with anterior infarction or short symptom duration, even at a PCI-related delay of approximately 120 min.³ While the magnitude of survival difference between PPCI and FT decreased as delay to PCI increased, at no point did mortality for PPCI exceed that with FT. These findings are concordant with the previous findings by Boersma and colleagues that were based on individual data from studies comparing FT with PPCI.⁴ Swedish registry data indicate a comparable outcome from PPCI and FT, even with a PCI-related delay of 240 min, and observations from both the French FAST-MI registry and the Vienna registry report comparable outcomes for patients treated with FT and PPCI with a PCI-related delay of 90 min.^{5–7}

The ESC STEMI guideline also relies upon analysis of the Comparison of Angioplasty and Pre-hospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) trial when recommending a ‘FMC-to-PPCI’ delay of 60 min.⁸ This non-prespecified subgroup analysis, based on 460 patients, claimed a lower mortality in patients randomised to FT versus PPCI among subjects presenting early. However, this finding did not reach statistical significance. A much larger meta-analysis including individual data from 6763 patients demonstrated superiority of PPCI over FT, in early as well as late incomers.⁴ This finding was also confirmed in the Swedish registry data.⁵ It seems that the aforementioned subgroup analysis from CAPTIM was weighted too heavily. Furthermore, findings from the CAPTIM substudy offer little value in substantiating a recommendation of ‘FMC to PPCI’ of <60 min,

Figure 1 Various delays when treating patients with ST-Elevation Myocardial Infarction (STEMI) with fibrinolysis or primary percutaneous coronary intervention (PPCI). 'Healthcare system delay' is the total delay from emergency medical service (EMS) call to PPCI. 'PCI-related delay' is the extra delay that one may use to perform PPCI instead of administering fibrinolysis and still achieve a mortality benefit from PPCI. First Medical Contact (either EMS call, EMS arrival on scene, or arrival at hospital according to regional STEMI system of care).



when the 'FMC to PPCI' delay must have been at least 100 min in the trial. The time from symptom onset to randomisation was 108 min in the CAPTIM trial, and the time to PPCI was 190 min, indicating that time from randomisation to PPCI was 82 min. The response time (EMS call to arrival on scene) is typically about 10 min, and the ambulance physicians must have used at least 10 min on scene before randomisation. A conservative estimate, thus, is a 'FMC to PPCI' delay of at least 102 min in this study. Consequently, neither the CAPTIM trial nor the NRMI analyses support a 'FMC to PPCI' delay of <60 min.

Creation of a clinical guideline is an immense task, and we commend the writing group for their efforts in creating a comprehensive and useful document summarising the available scientific data informing management of STEMI patients. The guidelines serve as a valuable resource, but the flow charts and suggestions may be more applicable for new STEMI networks in regions without previously established systems of care. For well-functioning STEMI networks, we believe that the best available evidence supports a PCI-related delay <120 min. If existing STEMI networks were to implement the shorter metrics introduced in the current guidelines, there is a risk of FT administration to patients where outcomes would be better with PPCI.

Finally, in regions with an ideal STEMI systems of care, with prehospital diagnosis and field-triage directly to large-volume PPCI centres, FMC is variably defined as time of EMS call⁹ or EMS arrival on scene. In regions that do not use prehospital diagnosis, FMC is simply the time of ambulance arrival at the hospital. In self-presenters, FMC is also time of arrival at the hospital (figure 1). It is necessary to standardise and differentiate recommendations of 'FMC to PPCI' depending upon whether FMC is EMS call or arrival at hospital because after all, the most important factor is rapid reperfusion with the most optimal strategy for the patient. When comparing regions based on observed 'FMC to PPCI' delays, it may erroneously seem that regions rightfully focusing upon prehospital diagnosis are performing inferiorly compared with regions that are not implementing prehospital

diagnosis, while the opposite is likely the case. In fact, if one were to incorporate current ESC guideline recommendations of 'FMC to PPCI delay below 60 min', in regions using prehospital diagnosis for field-triage to PCI centres with rapid treatment times, FT would be administered to more patients compared with regions without prehospital diagnosis even though total ischaemic times would have been shorter for the patients, or even more absurdly, regions could eliminate prehospital diagnosis, increasing the 'window of opportunity' for PPCI.

We recommend that for future guidelines, professional societies on both sides of the Atlantic acknowledge the current confusion about the terminologies on treatment delays in STEMI and uncertainties in utilising available data for information regarding the proper treatment for various patient subsets, and avoid recommendations that may have deleterious consequences. It is uncertain whether a pharmacoinvasive strategy in the future will qualify as an alternative reperfusion strategy. However, the Strategic Reperfusion Early After Myocardial Infarction trial found no mortality benefit but an increased risk of stroke in patients randomised to a pharmacoinvasive strategy compared to patients randomised to a PPCI strategy.¹⁰

Author affiliations

- ¹Department of Cardiology, Aarhus University Hospital in Skejby, Aarhus, Denmark
- ²Department of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
- ³Department of Cardiology, University of Leipzig-Heart Center, Leipzig, Germany
- ⁴Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
- ⁵Department of Cardiology, Heart Center, Tampere University Hospital, Tampere, Finland
- ⁶Department of Cardiology, Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, UK
- ⁷Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
- ⁸Department of Cardiology, Clinical Center of Serbia and Medical School of Belgrade, Belgrade, Serbia
- ⁹Department of Cardiology, Odense University Hospital, Odense, Denmark
- ¹⁰Department of Cardiology, AHEPA University Hospital, Thessaloniki, Greece
- ¹¹Department of Cardiology, Skane University Hospital, Lund, Sweden
- ¹²Department of Cardiology, Erasmus Medical Centre, Rotterdam, Netherlands

Table 1 Delays to PPCI observed in the references used for recommendation of a First Medical Contact (FMC) to PPCI delay below 60 min in the recent European Society of Cardiology 2012 STEMI-guidelines

References	Emergency medical service call to arrival on scene	On scene delay	Transport delay	Door-to-balloon delay (D2B)	Overall 'FMC to PPCI' delay
Pinto <i>et al</i> ²	NA	NA	NA	116 min*	NA but >>>D2B delay!
Steg <i>et al</i> ¹	NA	NA	NA	NA	NA but at least 102 min†

*In the Pinto *et al* reference D2B delays were presented for four groups varying from 91 to 179 min. The weighted mean D2B delay is presented here.

†None of the many papers from the CAPTIM trial have presented 'FMC to PPCI' delay. Time to PPCI was 190 min and time to randomisation was 108 min. Adding 10 min for emergency medical service response time and just 10 min on scene before randomisation, this would add up to a cumulative 'FMC to PPCI' delay of approximately 102 min.

Contributors CJT, EB and DSP made the first draft of the viewpoint. All coauthors critically revised the viewpoint, agreed on its content and accepted it for publication.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

- 1 Steg PG, James SK, Atar D, *et al.* ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *Eur Heart J* 2012;33:2569–619.
- 2 Pinto DS, Kirtane AJ, Nallamothu BK, *et al.* Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. *Circulation* 2006;114:2019–25.
- 3 Pinto DS, Frederick PD, Chakrabarti AK, *et al.* Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. *Circulation* 2011;124:2512–21.
- 4 Boersma E, The Primary Coronary Angioplasty vs. Thrombolysis (PCAT)-2 Trialist' Collaborative Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. *Eur Heart J* 2006;27:779–88.
- 5 Stenestrand U, Lindback J, Wallentin L, for the RIKS-HIA Registry. Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. *JAMA* 2006;296:1749–56.
- 6 Kalla K, Christ G, Karnik R, *et al.* For the Vienna STEMI registry group. Implementation of guidelines improves the standard of care. The Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). *Circulation* 2006;113:2398–405.
- 7 Danchin N, Coste P, Ferrieres J, *et al.* Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). *Circulation* 2008;118:268–76.
- 8 Steg PG, Bonnefoy E, Chabaud S, *et al.* Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. *Circulation* 2003;108:2851–6.
- 9 Terkelsen CJ, Sørensen JT, Maeng M, *et al.* System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. *JAMA* 2010;304:763–71.
- 10 Armstrong PW, Gershlick AH, Goldstein P, *et al.* Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. *N Engl J Med* 2013;368:1379–87.